Vincerx Pharma Common Net Income
| VINC Stock | USD 0.01 0.0003 2.36% |
As of the 16th of February 2026, Vincerx Pharma has the Semi Deviation of 12.43, coefficient of variation of 2146.74, and Risk Adjusted Performance of 0.0471. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vincerx Pharma Common, as well as the relationship between them.
Vincerx Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Vincerx Pharma's valuation are provided below:We have found one hundred nineteen available fundamental trend indicators for Vincerx Pharma Common, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Vincerx Pharma's current performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of February 16, 2026, Market Cap is expected to decline to about 30.1 M. In addition to that, Enterprise Value is expected to decline to about 24.6 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -58.8 M | -55.9 M | |
| Net Loss | -27.1 M | -28.4 M | |
| Net Loss | -27.1 M | -28.4 M | |
| Net Loss | (6.61) | (6.94) | |
| Net Income Per E B T | 1.19 | 1.23 |
Vincerx | Net Income | Build AI portfolio with Vincerx Stock |
Analyzing Vincerx Pharma's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Vincerx Pharma's current valuation and future prospects.
Latest Vincerx Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Vincerx Pharma Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vincerx Pharma Common financial statement analysis. It represents the amount of money remaining after all of Vincerx Pharma Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vincerx Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vincerx Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (30.07 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Vincerx Net Income Regression Statistics
| Arithmetic Mean | (14,215,325) | |
| Coefficient Of Variation | (142.39) | |
| Mean Deviation | 17,070,421 | |
| Median | (54,000) | |
| Standard Deviation | 20,240,752 | |
| Sample Variance | 409.7T | |
| Range | 65.3M | |
| R-Value | (0.73) | |
| Mean Square Error | 202.9T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (2,933,850) | |
| Total Sum of Squares | 6555T |
Vincerx Net Income History
Other Fundumenentals of Vincerx Pharma Common
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vincerx Pharma Net Income component correlations
Vincerx Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vincerx Pharma is extremely important. It helps to project a fair market value of Vincerx Stock properly, considering its historical fundamentals such as Net Income. Since Vincerx Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vincerx Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vincerx Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Vincerx diversify its offerings? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Vincerx Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Vincerx Pharma Common requires distinguishing between market price and book value, where the latter reflects Vincerx's accounting equity. The concept of intrinsic value - what Vincerx Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Vincerx Pharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vincerx Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Vincerx Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vincerx Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vincerx Pharma.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Vincerx Pharma on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Vincerx Pharma Common or generate 0.0% return on investment in Vincerx Pharma over 90 days. Vincerx Pharma is related to or competes with P3 Health, Dermata Therapeutics, Revelation Biosciences, Aclarion, Surrozen, and Purple Biotech. Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet med... More
Vincerx Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vincerx Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vincerx Pharma Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 24.92 | |||
| Information Ratio | 0.0426 | |||
| Maximum Drawdown | 127.9 | |||
| Value At Risk | (3.77) | |||
| Potential Upside | 10.0 |
Vincerx Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vincerx Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vincerx Pharma's standard deviation. In reality, there are many statistical measures that can use Vincerx Pharma historical prices to predict the future Vincerx Pharma's volatility.| Risk Adjusted Performance | 0.0471 | |||
| Jensen Alpha | 0.7623 | |||
| Total Risk Alpha | (0.50) | |||
| Sortino Ratio | 0.0299 | |||
| Treynor Ratio | 1.1 |
Vincerx Pharma February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0471 | |||
| Market Risk Adjusted Performance | 1.11 | |||
| Mean Deviation | 5.38 | |||
| Semi Deviation | 12.43 | |||
| Downside Deviation | 24.92 | |||
| Coefficient Of Variation | 2146.74 | |||
| Standard Deviation | 17.52 | |||
| Variance | 307.03 | |||
| Information Ratio | 0.0426 | |||
| Jensen Alpha | 0.7623 | |||
| Total Risk Alpha | (0.50) | |||
| Sortino Ratio | 0.0299 | |||
| Treynor Ratio | 1.1 | |||
| Maximum Drawdown | 127.9 | |||
| Value At Risk | (3.77) | |||
| Potential Upside | 10.0 | |||
| Downside Variance | 621.12 | |||
| Semi Variance | 154.51 | |||
| Expected Short fall | (10.67) | |||
| Skewness | 1.03 | |||
| Kurtosis | 23.0 |
Vincerx Pharma Common Backtested Returns
Vincerx Pharma appears to be not too volatile, given 3 months investment horizon. Vincerx Pharma Common owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0975, which indicates the firm had a 0.0975 % return per unit of risk over the last 3 months. By inspecting Vincerx Pharma's technical indicators, you can evaluate if the expected return of 0.75% is justified by implied risk. Please review Vincerx Pharma's Risk Adjusted Performance of 0.0471, coefficient of variation of 2146.74, and Semi Deviation of 12.43 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Vincerx Pharma holds a performance score of 7. The entity has a beta of 0.73, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vincerx Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vincerx Pharma is expected to be smaller as well. Please check Vincerx Pharma's maximum drawdown and the relationship between the semi variance and day typical price , to make a quick decision on whether Vincerx Pharma's existing price patterns will revert.
Auto-correlation | 0.11 |
Insignificant predictability
Vincerx Pharma Common has insignificant predictability. Overlapping area represents the amount of predictability between Vincerx Pharma time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vincerx Pharma Common price movement. The serial correlation of 0.11 indicates that less than 11.0% of current Vincerx Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vincerx Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vincerx Pharma Common reported net income of (30.07 Million). This is 108.81% lower than that of the Biotechnology sector and 142.93% lower than that of the Health Care industry. The net income for all United States stocks is 105.27% higher than that of the company.
Vincerx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vincerx Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vincerx Pharma could also be used in its relative valuation, which is a method of valuing Vincerx Pharma by comparing valuation metrics of similar companies.Vincerx Pharma is currently under evaluation in net income category among its peers.
Vincerx Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Vincerx Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vincerx Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vincerx Pharma's value.| Shares | Millennium Management Llc | 2025-06-30 | 0.0 | Sage Rhino Capital Llc | 2025-06-30 | 0.0 | Renaissance Technologies Corp | 2025-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Armistice Capital, Llc | 2025-03-31 | 0.0 | Sbi Securities Co Ltd | 2025-06-30 | 0.0 | Bank & Trust Co | 2025-06-30 | 50.0 | Goldman Sachs Group Inc | 2025-06-30 | 0.0 |
Vincerx Fundamentals
| Return On Equity | -31.36 | ||||
| Return On Asset | -1.98 | ||||
| Current Valuation | (4.92 M) | ||||
| Shares Outstanding | 5.23 M | ||||
| Shares Owned By Insiders | 4.11 % | ||||
| Shares Owned By Institutions | 5.25 % | ||||
| Number Of Shares Shorted | 137.2 K | ||||
| Price To Book | 0.03 X | ||||
| EBITDA | (31.46 M) | ||||
| Net Income | (30.07 M) | ||||
| Cash And Equivalents | 80.86 M | ||||
| Cash Per Share | 3.82 X | ||||
| Total Debt | 5.28 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 7.88 X | ||||
| Book Value Per Share | 0.40 X | ||||
| Cash Flow From Operations | (26.13 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (5.79) X | ||||
| Target Price | 200.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.76 | ||||
| Market Capitalization | 26.17 K | ||||
| Total Asset | 8.01 M | ||||
| Retained Earnings | (189.19 M) | ||||
| Working Capital | 1.13 M | ||||
| Net Asset | 8.01 M |
About Vincerx Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vincerx Pharma Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vincerx Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vincerx Pharma Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vincerx Pharma Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vincerx Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vincerx Pharma Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vincerx Pharma Common Stock:Check out You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Will Biotechnology sector continue expanding? Could Vincerx diversify its offerings? Factors like these will boost the valuation of Vincerx Pharma. If investors know Vincerx will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Vincerx Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Vincerx Pharma Common requires distinguishing between market price and book value, where the latter reflects Vincerx's accounting equity. The concept of intrinsic value - what Vincerx Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Vincerx Pharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Vincerx Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vincerx Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Vincerx Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.